TAS-102 study for the treatment of metastatic stomach cancer.
This is a clinical research trial of TAS-102, which is the drug under investigation for the treatment of metastatic stomach cancer. This means that TAS-102 has not been approved for use in the country of your residence and/or for use in subjects with your particular diagnosis, except in a clinical research trial. TAS-102, under the brand name Lonsurf® (trifluridine and tipiracil), was approved in the U.S. on 22 September 2015 for the treatment of patients with metastatic colorectal cancer.
View and download more information on this study here.